Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection

Journal of Infectious Diseases

Volumn 199, Issue 8, 2009, Pages 1112-1120

  Hoofnagle, Jay H ^a   Wahed, Abdus S ^c   Brown Jr , Robert S ^e   Howell, Charles D ^b   Belle, Steven H ^c,d  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Departments Biostatistics   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e New York Presbyterian Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; TREATMENT RESPONSE;

AFRICAN AMERICANS; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL;

EID: 65649134135     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597384     Document Type: Article

References (29)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert W, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14.
2. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin therapy for chronic hepatitis C. N Engl J Med 2006; 355:2444-51.
3. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36(Suppl 1):S3-20.
4. Strader DB, Wright T, Thomas DL, Seeff LD. Diagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver Diseases. Hepatology 2004; 39:1147-71.
5. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130:231-64.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al.Peginterferon alfa-2a (40kD) plus ribavirin in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
7. Shiffman ML, Suter F, Bacon BR, et al.Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. Accelerate Investigators. N Engl J Med 2007; 357:124-34.
8. Manns MP, McHutchison JG, Gordon SC, et al.Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
9. Fried MW, Shiffman ML, Reddy K, et al.Combination of peginterferon alfa 2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
10. McHutchison JG, Manns M, Patel K, et al.Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. International Hepatitis Interventional Therapy Group. Gastroenterology 2002; 123:1061-9.
11. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non- Hispanic whites. Atlantic Coast Hepatitis Treatment Group. N Engl J Med 2004; 350:2265-71.
12. Conjeevaram HS, FriedMW,Jeffers LJ, et al.Peginterferon and ribavirin treatment in African American and Caucasian American patients with chronic hepatitis C, genotype 1. Virahep-C Study Group. Gastroenterology 2006; 131:470-7.
13. Neumann AU, Lam NP, Dahari H, et al.Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-7.
14. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28:245-52.
15. Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002; 9:332-3.
16. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 1343-50.
17. Shudo E, Ribeiro RM, Perelson AS. Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters. J Viral Hepat 2008; 15:357-62.
18. Shudo E, Ribeiro RM, Perelson AS. Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b. J Viral Hepat 2008; 15:379-82.
19. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-72.
20. Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang JT, Hoofnagle JH. Mechanism of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology 2008; 47:306-20.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9.
22. Howell CD, Dowling TC, Paul M, et al.Peginterferon pharmacokinetics in African-American and Caucasian American patients with hepatitis C virus genotype 1 infection. Virahep-C Study Group. Clin Gastroenterol Hepatol 2008; 6:575-83.
23. Ishak K, Baptista A, Bianchi L, et al.Histologic grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
24. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York, NY: Wiley, 2000.
25. Taylor MW, Tsukahara T, Brodsky L, et al.Changes in gene express during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007; 81:3391-401.
26. Foy E, Li K, Wang C, et al.Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300:1145-8.
27. Lin W, Kim SS, Yeung E, et al.Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 2006; 80:9226-35.
28. Chen I, Borozan I, Feld J, et al.hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128:1437-44.
29. Feld JJ, Nanda S, Huang Y, et al.Hepatitis gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment responses. Hepatology 2007; 46:1326-8.